| MD Anderson Cancer Center’s Laurie McInnes Hughes Wins Arceneaux Award
As a child, Laurie McInnes Hughes, MSN, RN, FNP, lost her younger brother to leukemia. Little did she know the impact that experience would have on her life, both personally and professionally. Hughes, an advanced practice nurse in the Department of Surgical Oncology at The University of Texas M. D. Anderson Cancer Center, will receive the 2007 Ethel Fleming Arceneaux Outstanding Nurse-Oncologist Award, made possible by The Brown Foundation, Inc., at a ceremony June 19. "I am honored to have been selected for this award and to be a part of the M. D. Anderson team," says Hughes. "My colleagues are outstanding and share a compassion for our patients. Thats why Im here. I love what I do." Hughes commitment is "from the heart." "Throughout my brothers illness we could always count on the unparalleled compassion and selfless dedication the nursing staff shared with our family," she says.
Surviving the US health care system
Cynthia Kline knew exactly what was happening to her when she suffered a heart attack at her home in Cambridge, Mass. She took the time to call an ambulance, popped some nitroglycerin tablets she had been prescribed in anticipation of just such an emergency, and waited for help to arrive. On paper, everything should have gone fine. Unlike tens of millions of Americans, she had health insurance coverage. The ambulance team arrived promptly. The hospital where she had been receiving treatment for her cardiac problems, a private teaching facility affiliated with the Harvard Medical School, was just a few minutes away. The problem was, the emergency room at the hospital, Mount Auburn, was full to overflowing. And it turned her away. The ambulance took her to another nearby hospital but the treatment she needed, an emergency catheterization, was not available there.
Study Presented at ASCO Shows Encouraging Preliminary Results for ...
VANCOUVER and CARLSBAD, CA, June 2 /PRNewswire-FirstCall/ -- OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. today announced preliminary data from a Phase II clinical trial of OGX-011 in combination with docetaxel and prednisone in patients with metastatic hormone refractory prostate cancer (HRPC). Data were presented by Dr. Kim Chi, Study Chair and a medical oncologist at BC Cancer Agency - Vancouver Centre, representing the National Cancer Institute of Canada - Clinical Trials Group at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Eighty-one patients with metastatic or locally recurrent prostate cancer refractory to hormone therapy were randomized to one of two treatment arms to receive either 640 mg OGX-011 per week in combination with docetaxel and prednisone or docetaxel and prednisone alone.
|
